Up­dat­ed: Con­tra­Fect to ter­mi­nate PhI­II MR­SA an­tibi­ot­ic tri­al — stock cap­sizes

One year af­ter BAR­DA backed Con­tra­Fect’s MR­SA treat­ment, the Yonkers, NY-based biotech said Wednes­day it will stop its Phase III tri­al of the as­set ear­ly due to fu­til­i­ty.

The da­ta safe­ty mon­i­tor­ing board re­viewed clin­i­cal re­sponse da­ta from 84 pa­tients, look­ing at su­pe­ri­or­i­ty over the con­trol arm at two weeks, and rec­om­mend­ed the tri­al be stopped, the com­pa­ny said in a press re­lease. The Phase III tri­al was orig­i­nal­ly de­signed to test exe­ba­case — a lysin treat­ment that would dis­solve bac­te­ria cell walls — in 350 pa­tients with bac­teremia from MR­SA, in­clud­ing those with right-sided heart in­flam­ma­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER